| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
DOPG-Na does not target a specific protein. It is a phospholipid that forms liposomes and other artificial membranes. The compound is used for the generation of micelles, liposomes, and other artificial membranes. Its negative charge facilitates interactions with cationic molecules and biological membranes. DOPG is an anionic phospholipid derivative.
|
|---|---|
| ln Vitro |
In vitro, DOPG-Na is used as a component of liposomal formulations for drug delivery. It enhances membrane stability and modulates interactions with biological targets. Negatively charged liposomes prepared with DOPG have been found to possess the best loading capacity and encapsulation efficiency for peptide nucleic acid (PNA) oligomers.
|
| ln Vivo |
In vivo, DOPG-Na is used in liposomal drug delivery systems. It can be formulated into liposomes for the delivery of therapeutic agents. The compound's biocompatibility makes it suitable for in vivo applications.
|
| Enzyme Assay |
DOPG-Na is characterized using standard lipid analysis techniques such as TLC, HPLC, and mass spectrometry. Liposome formation and stability are assessed using dynamic light scattering (DLS) and zeta potential measurements. Encapsulation efficiency is measured by separating liposomes from free drug using size exclusion chromatography or ultracentrifugation.
|
| Cell Assay |
DOPG-Na is used in cell culture for liposome-mediated delivery of compounds. Cells are treated with DOPG-Na-containing liposomes, and cellular uptake or delivery efficiency is assessed. Fluorescently labeled cargo is used to track liposome uptake by flow cytometry or fluorescence microscopy.
|
| Animal Protocol |
DOPG-Na formulations are evaluated in animal models for drug delivery and pharmacokinetics. Animals are administered DOPG-Na liposomes encapsulating therapeutic agents, and biodistribution and efficacy are assessed. Tissue distribution of the encapsulated drug is measured by LC-MS/MS or radiolabeling.
|
| ADME/Pharmacokinetics |
DOPG-Na has a molecular formula of C42H78NaO10P and a molecular weight of 797.03 g/mol. It appears as a white to off-white powder. Purity is ≥98%. The compound is stable at -20°C for ≥2 years. It is suitable for liposomal and lipid nanoparticle (LNP) formulations.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for DOPG-Na are limited. It is used in research for drug delivery applications. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[ Ringhieri, P.; Avitabile, C.; Saviano, M.; Morelli, G.; Romanelli, A.; Accardo, A. The influence of liposomal formulation on the incorporation and retention of PNA oligomers. Colloid Surf. B 2016, 145, 462–469, doi.org/10.1016/j.colsurfb.2016.05.034]
|
| Additional Infomation |
DOPG-Na is a phospholipid widely used in liposomal drug delivery systems. It enhances membrane stability and modulates interactions with biological targets. The compound is a valuable tool for studying liposome formulation, drug delivery, and membrane biology. It is a pharmaceutical excipient used in infusions, injections, and depot formulations.
|
| Molecular Formula |
C42H78NAO10P
|
|---|---|
| Molecular Weight |
797.04
|
| Exact Mass |
796.523
|
| Elemental Analysis |
C, 63.29; H, 9.86; Na, 2.88; O, 20.07; P, 3.89
|
| CAS # |
67254-28-8
|
| PubChem CID |
23702460
|
| Appearance |
White to off-white solid powder
|
| LogP |
11.441
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
54
|
| Complexity |
948
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(CO)O)OC(=O)CCCCCCCC=CCCCCCCCC.[Na+]
|
| InChi Key |
IUVFCFQZFCOKRC-IPKKNMRRSA-M
|
| InChi Code |
InChI=1S/C42H79O10P.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h17-20,39-40,43-44H,3-16,21-38H2,1-2H3,(H,47,48);/q;+1/p-1/b19-17-,20-18-;/t39?,40-;/m1./s1
|
| Chemical Name |
1,2-Dioleoyl-sn-glycero-3-Phospho-rac-(1-glycerol) (Sodium Salt)
|
| Synonyms |
DOPG-Na; 1,2-Dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 1,2-Dioleoyl-sn-glycero-3-phosphoglycerol DOPG 18:1 (Δ9-cis) PG
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2546 mL | 6.2732 mL | 12.5464 mL | |
| 5 mM | 0.2509 mL | 1.2546 mL | 2.5093 mL | |
| 10 mM | 0.1255 mL | 0.6273 mL | 1.2546 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
